Commercial Capabilities in Suprachoroidal Delivery
The back of the eye is the location of many irreversible and debilitating ocular conditions, and our proprietary technology precisely delivers drug at the site of disease. With well over 10,000 injections performed to date with our patented SCS Microinjector®, our commercial, clinical and regulatory expertise establishes Clearside as the leader in delivery of a wide variety of therapeutic agents to the suprachoroidal space. All with one goal – to improve patient outcomes.
MAKING A DIFFERENCE FOR PATIENTS
We and our partners are dedicated to developing and delivering treatments that preserve and improve vision for people with serious back of the eye diseases. Clearside is the leader in suprachoroidal delivery with the first and only FDA-approved way to access the suprachoroidal space offering enhanced benefits for patients and physicians. Our therapeutic approach has proven versatility with clinical development ongoing in six different retinal diseases.
MAKING A DIFFERENCE FOR PATIENTS
We and our partners are dedicated to developing and delivering treatments that preserve and improve vision for people with serious back of the eye diseases. Clearside is the leader in suprachoroidal delivery with the first and only FDA-approved way to access the suprachoroidal space offering enhanced benefits for patients and physicians. Our therapeutic approach has proven versatility with clinical development ongoing in six different retinal diseases.
